Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of data supporting the effective use of its high-density microarray patch ...

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical ...

The Network Lead of Anglo West Africa at Roche Diagnostics, Mr Roberto Taboada, has called on the Federal Government to increase investment in Human Papillomavirus, noting that HPV is the second ...

DNA repair proteins act like the body's editors, constantly finding and reversing damage to our genetic code. Researchers ...

By its very nature, then, healthcare is personal, an N=1 equation where each person’s unique factors should determine ...

Researchers from Fujita Health University, Japan, observed a rise in adult central nervous system (CNS) infections, primarily ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...

(NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

The “Make America Healthy Again” commission is reviewing certain vaccines as some states push to restrict the use of COVID-19 ...